Shop in your local currency and language

Choose another country or region to see specific content for your location and shop online.

United Kingdom
Filtration

In situ leak testing, integrity testing and PUPSIT for flow kits using the manual drug product filtration system

Dec 22, 2025

Our manual drug product sterile filtration system has been designed to reliably complete PUPSIT, post-use filter integrity testing and in situ (point-of-use) leak testing of flow kits, supporting you in the regulatory requirements of EU GMP Annex 1.

In this study, we used flow kits with our filters sized from 1 inch (KA02) to 10 inch (NP6) capsules, positioning them in single and redundant filtration configurations, then conducting pre-use leak testing, filter wetting, followed by pre-use and post-use integrity tested using bubble point (BP) and forward flow (FF) test methods.

Results confirmed the reliability of the system with a 100% pass rate for:

  • 78 pre-use and post-use integrity tests
  • 29 pre-use leak tests

Introduction

Final drug product filtration prior to filling is an essential step in drug product manufacturing. This step ensures the product is sterile and safe prior to filling the final vials/syringes ready to be given to a patient. Therefore, it is imperative that filtration is completed in a robust manner ensuring all barriers to potential contamination are performing as required.

To mitigate risk of contamination, as part of a contamination control strategy, the update to the EU GMP Annex 1 regulatory guidelines recommends pre-use post-sterilization integrity testing (PUPSIT) of sterilizing-grade filters (1).

Performing PUPSIT with our manual drug product filtration system (see Fig 1) mitigates the potential risk of using flow kits that may have become damaged due to transportation, storage or manual installation in a process.

Manual drug product filtration system

Fig 1. Manual drug product filtration system in a redundant filtration set-up (two NP6 filters) equipped with an extra flush bag tray, featuring a Watson Marlow pump and Palltronic Flowstar V with stand.

This system works in conjunction with a Palltronic Flowstar filter integrity test instrument facilitating:

  • in situ leak testing
  • filter wetting
  • pre-use post-sterilization integrity testing (PUPSIT)
  • post-use integrity testing

Depending on process needs we can configure filters in the system, in either a single or redundant arrangement. Single flow kits process through a single sterilizing filter, while redundant flow kits are used to process through multiple filters in series, providing an additional layer of assurance by verifying the integrity of each filter independently.

In the manual drug product filtration system, we position air filters above each liquid filter to ensure the flow path is fully closed, allowing sterile air to be used for any leak/integrity test. In situ leak testing can be performed directly after flow kit installation, to ensure the full flow path is leak free prior to product commitment (and to protect operators from undesired product contact during filtration). Priming, flushing and pressurized soaking can also be performed manually prior to pre-use and post-use integrity testing. This ensures that filters are integral pre and post use filtration, minimizing the risk of contamination.

To show the reliability of the manual drug product filtration system, we present in this study, in situ leak testing and integrity testing performance data generated from typical application tests. A full range of filter sizes, 1 inch (KA02) to 10 inch (NP6) and filter arrangements (single and redundant) were used. Filter membranes included Fluorodyne™ II DFL, a 0.2 µm rated polyvinylidene fluoride (PVDF) sterilizing-grade membrane, and Supor™ EKV, a 0.2 µm rated polyethersulfone (PES) sterilizing-grade membrane. These filter membrane types were chosen as they are two of the most commonly used sterilizing-grade membranes for final sterile filtration of drug product.

MATERIALS AND METHODS

Table 1. Equipment used for this study

Part number Description
MANPUPSIT-EU Manual drug product filtration system
MANPUPSIT-PUMP-EU Peristaltic pump Watson Marlow 630 EU
FFS04R-LGR Palltronic Flowstar IV LGR filter integrity test instrument
MANPUPSIT-PLTFFS04 Platform for the Palltronic Flowstar IV or LGR filter integrity test instrument
AEDLGR005 Air evacuation mat for a 5 L biocontainer bag
AEDLGR010 Air evacuation mat for a 10 L biocontainer bag
AEDLGR020 Air evacuation mat for a 20 L biocontainer bag
LGRTPE20L Allegro™ tray for biocontainers up to 20 L

 

We used single and redundant flow kits for this study. Single flow kits are used to process through a single sterilizing filter, while redundant flow kits are used to process through multiple filters in series, providing an additional layer of assurance by verifying the integrity of each filter independently.

Table 2. Flow kits used for this study

Product code Description
6090-2192C Single PUPSIT flow kit with KA02DFL filter and Kleenpak™ Presto connectors
6090-2186U Single PUPSIT flow kit with KA1DFL filter and Kleenpak™ Presto connectors
6090-2186W Single PUPSIT flow kit with KA3DFL filter and Kleenpak™ Presto connectors
6090-2186R Single PUPSIT flow kit with NP6DFL filter and Kleenpak™ Presto connectors
6090-2186P Redundant PUPSIT flow kit with KA02DFL filters and Kleenpak™ Presto connectors
6090-2186H Redundant PUPSIT flow kit with KA2DFL filters and Kleenpak™ Presto connectors
6090-2192B Redundant PUPSIT flow kit with NP6DFL filters and Kleenpak™ Presto connectors
6090-2186G Redundant PUPSIT flow kit with NP5LEKV filters and Kleenpak™ Presto connectors
6090-2192D Standard PUPSIT inlet single-use flow kit with sampling, Kleenpak™ Presto connectors
6090-2134S Standard PUPSIT flush bag 5 L, Kleenpak™ Presto connectors
6090-2189D Standard PUPSIT flush bag 10 L, Kleenpak™ Presto connectors
6090-2190V Standard PUPSIT flush bag 20 L, Kleenpak™ Presto connectors
6090-2189E Standard PUPSIT flush bag 2 × 20 L, Kleenpak™ Presto connectors
730469 200 L biocontainer bag

 

The manual drug product filtration system includes six movable valves that can be manually removed and repositioned as needed to manage configurations effectively. Additionally, two flush bag trays can be positioned on shelves to hold 5 L, 10 L, 20 L or 2 × 20 L flush bags, with all flow kits gamma sterilized (except for the non-gamma sterilized FAT flow kits).

Flow kit leak testing

We performed flow kit leak testing prior to use. Two types of flow kit leakage tests can be applied using the Palltronic Flowstar IV LGR; the leak test applied to check for potential leaks in flow kit tubing and the single-use system (SUS) leak test performed to check biocontainers for potential leaks. With the manual drug product filtration system, we can check the entire installed flow kit for potential leaks. The following tests can be performed covering different flow path areas:

  • Leak test 1: Covers the full flow path from valve position MV001 to the flush bag clamp, keeping product outlet (MV006) closed. This is a flow kit leak test which checks potential leakage of the flow kit tubing.
  • Leak test 2: Covers the flow path from valve position MV001 to the flush bag, keeping the flush bag valve (MV005) open and product outlet (MV006) closed. This is a SUS leak test which checks potential leakage of the connected 2D flush bag.

The picture shows leak test 1 and 2

Fig 2. The picture shows leak test 1 (left) and leak test 2 (right) for the redundant filtration configuration of the manual drug product filtration system. The general flow path defined for each leak test is the same irrespective of configuration or size. Filter positions 1 and 2 are highlighted in the left picture. All six valve positions are highlighted in blue.

 

We leak tested the full range of flow kit combinations. The full flow kit list and parameters input for leak testing can be found in Tables 2 and 3, respectively. The maximum acceptable diffusive gas flow limit for each flow path was based on the volume and type of components used within each flow path studied. These values can be found in Table 7. Leak tests were performed at ambient temperature (15°C to 25°C). During the test we controlled the temperature to ± 1°C of the temperature at the start of the test. After completion of the SUS leak test, we fully evacuated the 2D biocontainers using an air evacuation mat with the required size.

Table 3. Leak testing parameters used in this study to perform leak tests on flow kits

Process parameter Value
Filter integrity test instrument Palltronic Flowstar IV LGR
Test gas Air
Leak test pressure (Leak test 1) 1200 mbar
SUS leak test pressure (Leak test 2) 50 mbar
Leak test time 600 s

* Maximum acceptable air flows can be found in Table 7.

 

We started the leak test sequence using the Palltronic Flowstar IV LGR integrity test instrument with a pressurization phase to the entered test pressure (see Fig 3). After this, the stabilization phase began with the stabilization time automatically controlled by the integrity test instrument; it finished as soon as the flow stabilized within defined limits. Once the stabilization phase was complete, the measurement phase commenced, and the diffusive gas flow was measured over the set test time.

During the first 150 s, the integrity test instrument uses values measured during the stabilization phase to calculate the average flow. The flow reported on the graph is the average flow value for the previous 150 s (see Fig 3). If the measured diffusive gas flow is less than or equal to the specified maximum acceptable flow limit (mL/min) the test is a “PASS”. If the measured diffusive gas flow is greater than the specified maximum acceptable flow limit (mL/min), the test is a “FAIL”.

Typical example of a flow kit leak test sequence

Fig 3. Typical example of a flow kit leak test sequence, (each phase of the leak test is labelled with vertical reference lines showing the transition point between each phase (#pressurisation phase and ##vent phase after test completion).

 

Filter integrity testing

The system accommodates in-line filters sized from KA02 to NP6 (0.2 m2 to 5.5 m2) and includes six valve positions. The valves can be manually removed and repositioned as needed to manage configurations effectively. Our study encompassed the full range of filter sizes available, positioned in both the filter 1 and filter 2 positions (Fig 2), and single or redundant filtration configurations. The PUPSIT and the post-use integrity testing of the filters were conducted using a Palltronic Flowstar IV LGR integrity testing device. Filter integrity tests were performed at ambient temperature (15°C to 25°C). At the start of the testing we controlled the temperature at ± 1°C of the temperature at the start of the test, to confirm the filter flow rate was stable before proceeding to measurement.

For PUPSIT, we prepared the filters and integrity tested in situ. We primed all filter capsules at 0.10 L/min (with the exception of KA02 being primed at 0.036 L/min and KA1 being primed at 0.073 L/min). This allowed a slow capsule filling of ~ 1” of filter cartridge media per minute and ensured effective venting. Each filter type was flushed to remove extractables and leachables and achieve successful membrane wetting (see Table 4). Forward flow and bubble point integrity testing were completed for each liquid filter installed. For integrity testing parameters see Table 5. RO water was used as product for the filtration runs.

Table 4. Filter flushing flow rate and time per capsule size

Filter product code Flow rate (mL/min) Flush time (min)
KA02DFL 36 5
KA1DFL 73 5
KA2DFL 150 5
KA3DFL 270 5
NP5EKV 490 5
NP6DFL 1000 5

 

Table 5. Filter integrity test parameters used in this study for forward flow and bubble point tests (minimum bubble point and forward flow acceptable air flow can be found in Table 7)

Process parameter Value
Filter integrity test instrument Palltronic Flowstar IV
Filter wetting fluid RO water
Test gas Air
Forward flow filter integrity test pressure 2760 mbar
Pre-stabilization pressure applied for KA02DFL 2760 mbar
Pre-stabilization time applied for KA02DFL 1200 s
Bubble point module factor KA02 = 0.05
KA1 = 0.1
KA2 = 0.2
KA3 = 0.4
NP5 = 0.5
NP6 = 1

 

We started the forward flow integrity test sequence using the Palltronic Flowstar IV integrity test instrument with a pressurization phase to the validated test pressure (see Fig 4). After this, the stabilization phase began with the stabilization time automatically controlled by the integrity test instrument; it finished as soon as the flow stabilized within defined limits. Once the stabilization phase was complete, the measurement phase commenced and the diffusive gas flow through the wetted filter membrane was measured over the set test time.

During the first 150 s the integrity test instrument uses values measured during the stabilization phase to calculate the average flow. The flow reported on the graph is the average flow value for the previous 150 s, (see Fig 4). If the measured diffusive gas flow is less or equal than the specified maximum acceptable flow limit (mL/min) the test is a “PASS”. If the measured diffusive gas flow is greater than the specified maximum acceptable flow limit (mL/min) the test is a “FAIL”.

Typical example of a Forward Flow integrity test sequence

Fig 4. Typical example of a forward flow integrity test sequence (each phase of the integrity test (pressurization, stabilization and measurement) is labelled with vertical reference lines showing the transition point into each phase. #pressurisation phase. ##vent phase after test completion).

 

The bubble point integrity test sequence using the Palltronic Flowstar IV LGR integrity test instrument starts with a pressurization phase to 80% of the entered minimum bubble point pressure. After this, and prior to the actual bubble point measurement phase, a leak test phase is performed to confirm that there is no gross leak/defect in the filter system under test. During the leak test phase, the instrument measures the gas flow occurring at this gas pressure and compares this against a limit value which is determined by setting a "module factor”. If the gas flow measured is below the limit value, the bubble point test proceeds and enters the measurement phase. Applied module factors for bubble point testing of filters are shown in Table 6. In the bubble point measurement phase, the bubble point is identified when two sequential pressure decay values are obtained that are significantly greater than the preceding values. If the measured bubble point pressure is equal or greater than the membrane specified minimum bubble point pressure, the test is a “PASS”. If the measured bubble point pressure is less than the membrane specified minimum bubble point pressure, the test is a ‘FAIL’.

Typical example of a Forward Flow integrity test sequence

Fig 5. Typical example of a bubble point integrity test sequence (each phase of the integrity test (pressurization, leak test and measurement) is labelled with vertical reference lines showing the transition point into each phase. #pressurisation phase. ##vent phase after test completion).

 

Results and discussion

The filters integrated into the manual drug product filtration system single-use flow kits passed all 64 pre-use and 14 post-use forward flow and bubble point integrity tests (see Table 6). All integrity tests passed first time, therefore filter wetting was performed once. The sample numbers are separated into two conditions; before use (pre-use) and after use (post-use). An example of the forward flow and bubble point integrity test execution by the Palltronic Flowstar IV LGR is shown in Figures 4 and 5, respectively. The integrity test results were completed with filters arranged in the two available configurations (single or redundant), in a range of sizes (KA02 to NP6) with two of our sterilizing-grade membrane types (Fluorodyne™ II DFL and Supor™ EKV) confirming the system reliability and integrity over a full range of processing applications.

Table 6. Summary of 78 filter integrity tests (forward flow and bubble point) performed for the manual drug product filtration system. Results reported based on membrane type and filter product code irrespective of filter position on the system. Due to time constraints, not every filter was re-tested post-use, as full filtration runs were not completed for all filters.

Filter product code Integrity test type Sample number Maximum acceptable flow (FF) /
Minimum bubble point pressure (BP)
Average measured flow (FF) /
bubble point pressure (BP) ± σ
Result
(PASS/FAIL)
KA02DFL Forward flow Pre-use = 5
Post-use = 1
≤ 0.5 mL/min Pre-use = 0.5 ± 0.0 mL/min
Post-use = 0.4 mL/min
PASS
KA02DFL Bubble point Pre-use = 5
Post-use = 1
≥ 3180.0 mbar Pre-use = 4050.0 ± 0.0 mbar
Post-use = 4050.0 ± 0.0 mbar
PASS
KA1DFL Forward flow Pre-use = 3
Post-use = 0
≤ 1.0 mL/min Pre-use = 0.7 ± 0.0 mL/min
Post-use = N/A
PASS
KA1DFL Bubble point Pre-use = 3
Post-use = 0
≥ 3180.0 mbar Pre-use = 4116.7 ± 76.4 mbar
Post-use = N/A
PASS
KA2DFL Forward flow Pre-use = 6
Post-use = 0
≤ 2.0 mL/min Pre-use = 1.3 ± 0.1 mL/min
Post-use = N/A
PASS
KA2DFL Bubble point Pre-use = 6
Post-use = 0
≥ 3180.0 mbar Pre-use = 4008.3 ± 37.6 mbar
Post-use = N/A
PASS
KA3DFL Forward flow Pre-use = 1
Post-use = 0
≤ 3.4 mL/min Pre-use = 2.6 mL/min
Post-use = N/A
PASS
KA3DFL Bubble point Pre-use = 1
Post-use = 0
≥ 3180.0 mbar Pre-use = 3450.0 mbar
Post-use = N/A
PASS
NP5LEKV Forward flow Pre-use = 4
Post-use = 0
≤ 7.5 mL/min Pre-use = 5.3 ± 0.2 mL/min
Post-use = N/A
PASS
NP5LEKV Bubble point Pre-use = 4
Post-use = 0
≥ 3320.0 mbar Pre-use = 3850.0 ± 70.7 mbar
Post-use = N/A
PASS
NP6DFL Forward flow Pre-use = 13
Post-use = 6
≤ 12.0 mL/min Pre-use = 8.3 ± 0.3 mL/min
Post-use = 7.9 ± 0.3 mL/min
PASS
NP6DFL Bubble point Pre-use = 13
Post-use = 6
≥ 3180.0 mbar Pre-use = 3903.8 ± 77.6 mbar
Post-use = 4000.0 ± 31.6 mbar
PASS

* N/A = Not applicable.

 

In-situ flow kit leak testing

Drug product sterile filtration is the key process step to ensure the product is fully sterile prior to final filling where automated in situ (point-of-use) leak testing of flow kits helps to mitigate the potential risk of using damaged flow kits due to transportation, storage and manual installation.

The manual drug product filtration system flow path passed all 27 pre-use leak tests performed (see Table 7). The 27 leak tests encompassed the full range of filtration flow paths available on the system. No leaks were detected in the flow kits confirming that the system flow path was closed prior to the commitment of product, minimizing the risk of contamination.

Table 7. Summary of 27 in situ leak tests performed with the manual drug product filtration system. These results includes both flow kits (Leak test 1) and flow kits with biocontainers (Leak test 2). Results reported are based on the type of leak test (1 or 2) and filter type. The applied test parameters for both tests are shown in Table 3.

Filter configuration and
part number
Leak test type Sample number Maximum acceptable flow
(mL/min)
Average actual flow ± σ
(mL/min)
Result
(PASS/FAIL)
Single KA1DFL 1 3 1.6 0.2 ± 0.1 PASS
Single KA3DFL 1 1 1.7 0.1 PASS
Single NP6DFL 1 3 2.2 0 PASS
Redundant KA02DFL 1 1 1.7 0.2 PASS
Redundant KA2DFL 1 3 1.8 0.4 ± 0.6 PASS
Redundant NP5LEKV 1 2 2.3 0.3 PASS
Redundant NP6DFL 1 1 2.9 0 PASS
Flush bag: 5 L 2 2 3.0 1.0 ± 0.2 PASS
Flush bag: 10 L 2 4 6.5 2.0 ± 1.5 PASS
Flush bag: 20 L 2 5 10.0 2.8 ± 1.8 PASS
Flush bag: 2 × 20 L 2 2 48.0 9.3 ± 0.3 PASS

 

Conclusion

We have optimized the manual drug product filtration system for PUPSIT, post-use filter integrity testing and in situ leak testing of the entire single-use flow kit path prior to drug product commitment, to reduce the risk of product contamination for large scale GMP applications.

The system also has the ability to perform in situ priming, wetting and flushing of filters, and the option to perform pressurized static soaks on filters (to further improve filter wetting), providing a reliable and robust process for integrity testing on filter arrangements in single and redundant configurations (sized from KA02 to NP6 format). This mitigates the risk of false failures and promotes the efficient manufacture of drug products.

References

  1. European Commission Guidelines, The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use - Annex 1 Manufacture of Sterile Medicinal Products. 2022.
  2. Manual drug product filtration system Operating Instructions, Document number: 29806919, Revision AA
  3. USD2594(8a) – Instructions for Use Palltronic Flowstar IV LGR Instrument

CY55987

Learn more about the manual drug product filtration system
Discover more about the manual drug product filtration system and find out how it can efficiently perform in situ leak testing, integrity testing and PUPSIT for single use flow kits

Did you find what you were looking for?